This inventor holds 2 USPTO granted patents and 3 published patent applications. Top assignee: Merrimack Pharmaceuticals, Inc.. Active years: 2017-2019.
Company Filing History:
Years Active: 2017-2019
Title: Defne Yarar: Innovator in Cancer Therapy Optimization
Introduction
Defne Yarar is a prominent inventor based in Brookline, MA (US). She has made significant contributions to the field of cancer therapy through her innovative research and patented methods. With a focus on optimizing treatment for patients with non-hematological cancers, her work is paving the way for more effective therapies.
Latest Patents
Defne Yarar holds 2 patents that focus on biomarker profiles for predicting outcomes of cancer therapy with ERBB3 inhibitors and/or chemotherapies. Her latest patents provide methods for optimizing therapy, treating patients, and selecting those who will benefit from treatment for various cancers, including gynecological cancers. The methods involve determining the potential benefits of treatment with an ErbB3 inhibitor, either alone or in combination with other therapies, based on specific biomarkers measured in biological samples from patients. These biomarkers may include proteins and nucleic acids that play a role in ErbB-mediated signal transduction.
Career Highlights
Defne Yarar is currently associated with Merrimack Pharmaceuticals, Inc., where she continues her research and development efforts. Her work is instrumental in advancing cancer treatment methodologies and improving patient outcomes.
Collaborations
Defne collaborates with notable colleagues, including Bambang Adiwijaya and Akos Czibere, to further enhance the impact of her research in the field of oncology.
Conclusion
Defne Yarar's innovative contributions to cancer therapy optimization highlight her dedication to improving patient care through scientific advancements. Her work exemplifies the importance of research in developing effective treatment strategies for cancer patients.